4 stories mentioning ASX:TTXUpdated 1h ago
Every FINWIRES story that references ASX:TTX, newest first.
Tetratherix (ASX:TTX) completed its share purchase plan, receiving applications totaling AU$639,644 at an issue price of AU$6 apiece, according to a Monday filing with the Australian bourse.Proceeds will be used to fund production expansion, strategic partnerships, customer success, digitalization, working capital, and offer costs, the filing said.
Tetratherix (ASX:TTX) said further research validation of the Tetramatrix platform polymer product confirmed it forms a protective, adhesive carrier on the nasal lining, guarding compounds from degradation and enabling direct absorption into the bloodstream, according to a Tuesday Australian bourse filing.The peer-reviewed study applied the product to insulin, confirming greater than 99% encapsulation, stability, protection from enzymatic degradation, and statistically superior compound delivery to the bloodstream and brain compared with unformulated insulin.Another study tested the product against bovine serum albumin and showed high encapsulation efficiency, stability over four weeks when refrigerated, zero cytotoxicity, greater deposition in the olfactory region, and a statistically significant increase in the tightening of nasal cell junctions.The studies were led by researchers at the Woolcock Institute of Medical Research, a Tetratherix research collaborator.Its shares rose 1% in recent trading on Tuesday.
Tetratherix (ASX:L) said it has received firm commitments from new and existing institutional investors to raise AU$15 million through a placement at AU$6 per share, representing a 2% discount to the 10-day volume-weighted average price of AU$6.12, according to a Thursday Australian bourse filing.The company said tranche 1 shares are anticipated to settle on June 3, while tranche 2 shares issued to directors are subject to shareholder approval at a general meeting.The company will also offer a share purchase plan (SPP) to existing eligible shareholders to raise a further AU$2 million, with proceeds from the placement and SPP to be used to fund production expansion, strategic partnerships, customer success, digitalization, working capital, and transaction costs.The company's shares tumbled 6% in recent Thursday trade.
Tetratherix (ASX:TTX) is reportedly looking to raise around AU$15 million from an equity raising at AU$6 per share, and it has brought in Barrenjoey Capital Partners and Morgans, the Australian Financial Review (AFR) reported on Tuesday.The offering is said to be cornerstoned by a global healthcare investor, the report said.The firm requested a halt in trading of its shares from the open of trading on Tuesday in connection with a proposed material capital raising, according to a same-day Australian bourse filing.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
